Clinical Trials Logo
  1. Home
  2. Hypertrophy, Left Ventricular
  3. NCT00616902

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 — PRIMO II  

Hypertrophy, Left Ventricular Clinical Trial

Official title:
Clinical Study Protocol M10-221 The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

Clinical Trial Summary

To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00616902
Study type Interventional
Source Abbott
Contact
Status Terminated
Phase Phase 3
Start date January 2009
Completion date May 2009
View Details
See also
  Status Clinical Trial Phase
Completed NCT02237339 - Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension? Phase 4
Completed NCT00041418 - Cardiac MR of Subclinical CVD: Impact of Age N/A
Completed NCT00005373 - Racial Differences in the Coronary Microcirculation N/A
Recruiting NCT00989508 - Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Phase 2/Phase 3
Completed NCT03482934 - Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate
Completed NCT03415750 - Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants Phase 4
Completed NCT02973607 - Effects of a Reduction in Renal Function on Cardiovascular Structure and Function
Completed NCT03749551 - Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study
Completed NCT01976689 - New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation N/A
Active, not recruiting NCT05713916 - Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy N/A
Recruiting NCT00552851 - Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Phase 4
Active, not recruiting NCT03094143 - Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS N/A
Completed NCT02444689 - EMPower: Electronic Media Powering Positive Health Changes in Youth N/A
Completed NCT00108082 - The CLEVER Study - Coreg And Left Ventricular Mass Regression Phase 3
Withdrawn NCT03315832 - Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study Phase 2/Phase 3
Completed NCT03180593 - Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH Phase 4
Completed NCT01144039 - Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair Phase 4
Completed NCT00045994 - The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling Phase 2
Active, not recruiting NCT02599480 - Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure Phase 2
Active, not recruiting NCT04862273 - Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis